PATENT CLAIM ANALYSIS

Application Number: 15972996
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["514", "064000"]

Abstract:
Compounds according to Formula I and Formula II are potent inhibitors of Arginase I and II activity: where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , D, M, X, and Y are defined as set forth in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use for treating or preventing a disease or a condition associated with arginase activity.

Claim (Index 47):
The method according to  claim 27 , wherein the disease or condition is selected from renal disease, asthma, inflammation, psoriasis, leishmaniasis, ischemia reperfusion injury, neurodegenerative diseases, wound healing, hepatitis B virus (HBV),  H. pylori  infections, fibrotic diseases, arthritis, renal disease, sickle cell disease (SCD), candidiasis, periodontal disease, keloids, adenotonsillar disease, cerebral vasospasm, African sleeping sickness, Chagas' disease, malaria, and Goodpasture's syndrome.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 93.0
- Lexical Diversity: 1.56897
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14471244', '15207902', '13276806', '14614115', '15540888']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8185367808004307
- 35 USC 102 Novelty (BERT): 0.5561176081218443
- Combined Prediction Score: 0.7922948635325721
- Mean Citation Score: 379.857086
- Max Citation Score: 434.2485
- Similarity Product: 340.0277019748092

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test